Blood test could prevent deadly virus in transplant patients
NCT ID NCT06449586
Summary
This study aims to see if a blood test that measures the immune system's strength against a common virus (CMV) can help doctors decide how long to give a preventive antiviral drug. It involves 250 adults who have received a stem cell transplant for blood cancer. The goal is to better prevent late-onset CMV infections, which can be serious, by personalizing the length of preventive treatment based on each patient's immune recovery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital of Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, China
-
Shanghai Liquan Hospital
Shanghai, China
-
The First Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
Tongji Hospital of Huazhong University of Science and Technology, Wuhan
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.